Long-Term Natural History of Autoimmune Gastritis: Results From a Prospective Monocentric Series
- PMID: 38050966
- DOI: 10.14309/ajg.0000000000002619
Long-Term Natural History of Autoimmune Gastritis: Results From a Prospective Monocentric Series
Abstract
Introduction: The natural history of autoimmune gastritis (AIG) has been poorly described. In this study, we report the long-term natural history and clinical clustering of the full spectrum of AIG, from the potential to the complicated stage.
Methods: Prospective single-center study conducted in a tertiary referral center. Patients with AIG at any stage (0 = potential; 1 = early; 2 = florid; 3 = severe; and 4 = complicated) were enrolled (January 2000-December 2022). The histopathological evolution, the clinical presentation, and the correlates of evolution of potential AIG were assessed.
Results: Four hundred ninety-eight patients with AIG (mean age 56.7 ± 15.2 years, F:M ratio 2.5:1) were included, of whom 93 experienced potential AIG. The maximum disease duration was 27 years (median 18, interquartile range 14-23), while the overall median follow-up was 52 months (interquartile range 12-95). Age was significantly lower in stage 0 compared with that in the other stages. Accidental histologic evidence and hematologic findings were the most common clusters of diagnosis. The overall median rate of progression was 7.29 per 100 persons/yr (95% confidence interval [CI] 6.19-8.59), while the stage-specific rates of progression were 10.85 (stage 0; 95% CI 7.75-15.18), 14.83 (stages 1-2; 95% CI 11.89-18.49), and 2.68 (stage 3; 95% CI 1.88-3.84). Newly onset neoplastic complications at follow-up occurred in 41/483 patients (8.5%; 23 neuroendocrine tumors and 18 epithelial dysplasia). No cases of adenocarcinoma were noticed. Male sex was associated with a greater likelihood of evolving from potential AIG to overt AIG.
Discussion: AIG is a progressive disorder, with a virtually absent risk of gastric adenocarcinoma. Patients with potential AIG should be monitored because they carry a high risk of evolving into overt AIG.
Copyright © 2024 by The American College of Gastroenterology.
Comment in
-
Multidisciplinary Collaborative Team for Screening of Autoimmune Gastritis.Am J Gastroenterol. 2024 Jun 1;119(6):1207. doi: 10.14309/ajg.0000000000002793. Epub 2024 Mar 27. Am J Gastroenterol. 2024. PMID: 38661170 No abstract available.
Similar articles
-
Time course and risk factors of evolution from potential to overt autoimmune gastritis.Dig Liver Dis. 2022 May;54(5):642-644. doi: 10.1016/j.dld.2021.10.001. Epub 2021 Oct 31. Dig Liver Dis. 2022. PMID: 34732311
-
Gastric cancer in autoimmune gastritis: A case-control study from the German centers of the staR project on gastric cancer research.United European Gastroenterol J. 2020 Mar;8(2):175-184. doi: 10.1177/2050640619891580. Epub 2019 Nov 26. United European Gastroenterol J. 2020. PMID: 32213076 Free PMC article.
-
Natural history of autoimmune atrophic gastritis: a prospective, single centre, long-term experience.Aliment Pharmacol Ther. 2019 Dec;50(11-12):1172-1180. doi: 10.1111/apt.15540. Epub 2019 Oct 17. Aliment Pharmacol Ther. 2019. PMID: 31621927
-
Endoscopic features and clinical importance of autoimmune gastritis.Dig Endosc. 2022 May;34(4):700-713. doi: 10.1111/den.14175. Epub 2021 Nov 10. Dig Endosc. 2022. PMID: 34674318 Review.
-
Autoimmune Gastritis in Pediatrics: A Review of 3 Cases.J Pediatr Gastroenterol Nutr. 2020 Feb;70(2):252-257. doi: 10.1097/MPG.0000000000002547. J Pediatr Gastroenterol Nutr. 2020. PMID: 31978028 Review.
Cited by
-
Autoimmune Gastritis and Hypochlorhydria: Known Concepts from a New Perspective.Int J Mol Sci. 2024 Jun 21;25(13):6818. doi: 10.3390/ijms25136818. Int J Mol Sci. 2024. PMID: 38999928 Free PMC article. Review.
-
Autoimmune Atrophic Gastritis: A Clinical Review.Cancers (Basel). 2024 Mar 28;16(7):1310. doi: 10.3390/cancers16071310. Cancers (Basel). 2024. PMID: 38610988 Free PMC article. Review.
References
-
- Neumann WL, Coss E, Rugge M, et al. Autoimmune atrophic gastritis--pathogenesis, pathology and management. Nat Rev Gastroenterol Hepatol 2013;10(9):529–41.
-
- Lenti MV, Rugge M, Lahner E, et al. Autoimmune gastritis. Nat Rev Dis Primers 2020;6(1):56.
-
- Lenti MV, Facciotti F, Miceli E, et al. Mucosal overexpression of thymic stromal lymphopoietin and proinflammatory cytokines in patients with autoimmune atrophic gastritis. Clin Transl Gastroenterol 2022;13(7):e00510.
-
- Green R, Allen LH, Bjørke-Monsen AL, et al. Vitamin B12 deficiency. Nat Rev Dis Primers 2017;3:17040.
-
- Lenti MV, Miceli E, Cococcia S, et al. Determinants of diagnostic delay in autoimmune atrophic gastritis. Aliment Pharmacol Ther 2019;50(2):167–75.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
